Concepedia
Statistics
Publications
8
Citations
306
H-Index
Active since
2006
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)
National Taiwan University Hospital
University of California, Los Angeles
Massachusetts General Hospital
Kindai University
A.B. Siegel is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and liver cancer.
Publications per year
2006–2020
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
Anthony B. El-Khoueiry, Cathryn Rankin, A.B. Siegel et al. · British Journal of Cancer · 2014 · 121 citations · Full text
Medicine, Oncology, Pharmacotherapy +17
A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Josep M. Llovet, Karen Shepard, RS Finn et al. · Annals of Oncology · 2019 · 69 citations · Full text
Medicine, Oncology, Pharmacology +13
Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein
Jonathan D. Schwartz, M. Schwartz, Deborah Lehrer et al. · Journal of Clinical Oncology · 2006 · 56 citations
Medicine, Oncology, Pharmacotherapy +11
1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation
Arndt Vogel, Andrew X. Zhu, Ann‐Lii Cheng et al. · Annals of Oncology · 2020 · 15 citations
Medicine, Oncology, Radiology +15
Prevalence of high‐risk human papilloma virus among women with hepatitis C virus before liver transplantation
P Tarallo, Janice Smolowitz, Damaris Carriero et al. · Transplant Infectious Disease · 2013 · 12 citations · Full text
Medicine, Oncology, Cancer Screening +16
1–5 of 8